Biotechnology major Biocon Biologics on Tuesday said Ireland's health regulator has reported some deficiencies in the manufacturing process at the company's plant in Bengaluru.
The Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP (Good Manufacturing Practice) inspection of one of Biocon Biologics' new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, between March 28 and April 1, 2022, a Biocon Biologics spokesperson said in a regulatory filing.
"The inspection report contains no 'critical' observations and only one of the deficiencies is categorised as 'major' which is being addressed expeditiously in consultation with the regulatory agency," the spokesperson added.
The facility will help the company address the additional requirements of products in the European Union market, the spokesperson noted.
Biocon Biologics is a subsidiary of Biocon Ltd.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.